Amphista Therapeutics
@amphistathera
A global leader in the discovery and development of next generation targeted protein degradation therapeutics with the potential to treat a range of diseases.
ID: 1479122524810141697
https://amphista.com/ 06-01-2022 16:08:23
232 Tweet
567 Takipçi
35 Takip Edilen
Our Interim CEO, Beverley Carr, Chief Scientific Officer, Louise Modis and Senior Director of Business Development and Operations, John Goodall, will be on the ground in London for the 10th annual LSX Leaders World #Congress on 29-30 April. informaconnect.com/lsx-world-cong… #TPD
Amphista has been shortlisted for the 2024 Cambridge Independent Science and Technology Awards in the Award for Innovation category! Congratulations to the entire Amphista team and all the other companies and individuals shortlisted. #Shortlisted #DrugDiscovery #TPD #SciTechAwards
Thank you Cambridge Independent for a great evening at the Science and Technology Awards last night. Amphista was shortlisted for The Award for Innovation and while we didn’t win, we were thrilled to be included amongst a strong field of innovators. Congratulations to all finalists!
ICYMI – Last week, BioCentury covered our unveiling of a new mechanism of action for the degradation of BRD9. Read the full piece by Danielle Golovin here: biocentury.com/article/652493… #BioCentury #DrugDiscovery #Biotech #TargetedProteinDegradation #CeTPD #TPD
Victoria Lovatt, VP of Intellectual Property at Amphista, recently shared her expertise at the World Intellectual Property Organization (WIPO) Patent Drafting Training Program. Thank you, WIPO, for inviting Victoria to share her expertise and contribute to the next generation of high-quality patent professionals! #TPD
Exciting week ahead for the Amphista team! Richard Sherhod, Senior Director of Chemoinformatics & Computational Chemistry, will attend RDKit User Group Meeting in Zurich and James Lynch, Director of Oncology will be at the ESMO - Eur. Oncology Congress in Barcelona. #DrugDiscovery #TPD